Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer
Recruiting now
Conditions studied: Breast Cancer, Neoadjuvant Therapy, Pathological Response, Invasive Breast Carcinoma, MicroRNAs
In brief
This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.
Key facts
- Study ID
- NCT07289282
- Run by
- Atlas University
- People needed
- 80
- Starts
- 2025-12-15
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-03-31
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed breast cancer
- Planned to receive neoadjuvant chemotherapy
- Biologically female
- Age ≥ 18 years
- Ability to provide informed consent
- Adequate organ function to receive standard NAC (based on routine clinical evaluation)
You may not qualify if…
- Presence of metastatic disease at diagnosis
- Prior systemic chemotherapy for breast cancer
- Pregnancy or breastfeeding
- Active infection or uncontrolled comorbid conditions interfering with study participation
- Any condition preventing collection of blood samples
Where it is running
- Istanbul Atlas University Faculty of Medicine — Istanbul, Turkey (Türkiye) (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.